Question
COMT inhibitor
Q18 0.3 marks Short Answers ★ ✓
Answer
Entacapone — inhibits catechol-O-methyltransferase (COMT), the peripheral enzyme that degrades levodopa, thereby increasing levodopa’s plasma half-life and bioavailability when used as an adjunct in Parkinson’s disease therapy.
1 Antiparkinsonian Drugs
Other Years Asked
1 Drugs used to treat Parkinsonism. Describe the Mechanism of action and adverse
effects of levodopa. 2024 March (Supplementary) (2019 Scheme) Short Essay · 8 marks 2 Enumerate four groups of drugs used in the treatment of Parkinson’s disease. Describe the
pharmacological actions and adverse effects of levodopa. What is the advantage of combining
levodopa with the peripheral decarboxylase inhibitor. (2+3+1= 6) 2015 September (Supplementary) (2010 Scheme) Essay · 6 marks 3 Pharmacotherapy of Parkinsonism. 2022 July (Supplementary) (2019 Scheme) Short Answer · 4 marks 4 Levodopa 2020 February (Supplementary) (2010 Scheme) Short Note · 3 marks 5 COMT inhibitors. 2016 October (Supplementary) (2010 Scheme) Short Note · 3 marks 6 The medication preferred in the treatment of drug-induced parkinsonism is 2025 March (Supplementary (SAY)) (2019 Scheme) MCQ · 1 mark 7 COMT inhibitors 2018 July (Supplementary) (2010 Scheme) Short Answer · 1 mark 8 Idiopathic parkinsonism 2014 March (2010 Scheme) Short Answer · 1 mark 9 Parkinson’s disease 2016 February (2010 Scheme) Short Answer · 1 mark 10 Bromocriptine 2019 July (Supplementary) (2010 Scheme) Short Answer · 1 mark 11 Peripheral decarboxylase inhibitor 2022 May (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 12 COMT inhibitors. 2025 August (Supplementary) (2010 Scheme) Short Answer · 0.3 marks 
